"Revenue growth lags strong deal wins due to macro delays"
Latest test: Constant currency QoQ growth was 1.2%, while TCV was $12B including 3 mega deals.
TCS — Bear Case History
Tracking the market's concerns across 12 quarters.
"North America revenue decline signals prolonged weakness"
Latest test: Constant currency revenue declined 3.1% YoY in Q1 FY26, driven by North America weakness.
"Revenue growth remains muted despite strong deal wins"
Latest test: Revenue grew 2.4% YoY in Q2 FY26, while TCV was $10 billion, up 16% YoY.
"Margin improvement may be unsustainable due to headcount decline"
Latest test: Operating margin was 25.2% in Q2 FY26, up 70 bps QoQ, while headcount fell 3% QoQ to 509,314.
"Headcount decline signals underlying demand weakness"
Latest test: -5,600
"Margin recovery to 26% delayed again"
Latest test: 25.2%, flat QoQ
"AI cannibalization may outpace AI revenue growth"
Latest test: AI revenue is >$2.3B annualized, but management admitted traditional services may taper as AI productivity benefits are passed to clients.
"BFSI vertical recovery delayed beyond expectations"
Latest test: BFSI revenue declined 3.2% YoY in Q4 FY24.
"BFSI weakness continues with no recovery timeline"
Latest test: -3% YoY
"BSNL revenue uncertainty persists"
Latest test: Revenue flat; no formal PO received; no timeline provided
"Client discretionary spend volatility persists"
Latest test: CEO stated 'short-term demand still remains not very clear or volatile' and highlighted client caution on discretionary spend.
"Deal TCV decline signals weakening demand pipeline"
Latest test: $8.6B vs $10.2B, down 15.7% YoY; H1 TCV down 20% YoY
"Dependence on BSNL for India growth"
Latest test: 61.8% YoY
"GenAI revenue impact remains negligible"
Latest test: 4
"Large deal margins may be initially dilutive"
Latest test: EBITDA margin improved to 24.3% from 23.2%. CFO acknowledged large deals may have lower margins initially but said portfolio-level margins are managed.
"Life sciences and healthcare recovery uncertain"
Latest test: Life sciences and healthcare revenue declined 4.3% YoY in Q3 FY25.
"Margin improvement capped by wage hikes and SG&A"
Latest test: Operating margin was 25.3% in Q4 FY26, up 10 bps QoQ. Management guided for 150-200 bps margin headwind from wage hikes in Q1 FY27.
"Margin improvement may be temporary; 26-28% band elusive"
Latest test: EBITDA margin was 24.3%, up 110 bps QoQ from 23.2%. Management reiterated the 26-28% band but said 'hopefully soon' without a specific timeline.
"Margin improvement unsustainable due to excess capacity"
Latest test: Operating margin was 24.5% in Q1 FY26, down YoY; CFO acknowledged carrying excess capacity due to demand contraction.
"Margin pressure from growth market investments and BSNL tapering"
Latest test: 24.1% vs 24.7%, down 60 bps sequentially
"North America revenue recovery remains elusive"
Latest test: Constant currency revenue declined 0.6% YoY in FY26, with North America being a major contributor to the weakness.
"Order book lumpiness and delayed closures"
Latest test: $8.3B vs $12.4B in Q4 FY24, down 33% QoQ
"Restructuring costs and headcount reductions impact morale"
Latest test: Headcount flat at 582,163; ~1,800 released; restructuring to continue
"US tariff uncertainty delays discretionary spending"
Latest test: Order book TCV of $12.2B (second highest); management cited delays in decision-making and project starts for discretionary investments